Irritable Bowel Syndrome (IBS) is a prevalent disorder of gut-brain interaction, affecting ≈11% of the global population. This meta-analysis identified consistent gut microbiome signatures associated…
We rarely discuss early trials, but this month we highlight a phase 2 trial that offers a promising new mechanism of action for our patients…
Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective…
The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist…
The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist…
Post written by Julien D. Schulberg, MBBS, PhD, and Michael A. Kamm, MBBS, PhD, from the Department of Gastroenterology, St Vincent’s Hospital, and the Department of Medicine, U…
Background The microbiota is emerging as a key factor in the predisposition to insulin resistance and obesity. Objective To understand the interplay among gut microbiota…
Background GI cancers pose an increasing global health burden, with their impact on the working-age population (WAP) aged 15–64 years remaining largely unexplored despite the…
You’ve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your…
The success of Mayo Clinic’s first paired living-donor liver transplantation may pave the way for expanded access and more “timely transplant” for patients in need,…
Although underpowered and incomplete, Neo-AEGIS provides the largest comprehensive randomised dataset for patients with adenocarcinoma of the oesophagus and oesophagogastric junction treated with perioperative chemotherapy…
